Literature DB >> 19498463

Tumour-experienced T cells promote NK cell activity through trogocytosis of NKG2D and NKp46 ligands.

Carolina I Domaica1, Mercedes B Fuertes, Lucas E Rossi, María V Girart, Damián E Avila, Gabriel A Rabinovich, Norberto W Zwirner.   

Abstract

Natural killer (NK) cells trigger cytotoxicity and interferon (IFN)-gamma secretion on engagement of the natural-killer group (NKG)2D receptor or members of the natural cytotoxicity receptor (NCR) family, such as NKp46, by ligands expressed on tumour cells. However, it remains unknown whether T cells can regulate NK cell-mediated anti-tumour responses. Here, we investigated the early events occurring during T cell-tumour cell interactions, and their impact on NK cell functions. We observed that on co-culture with some melanomas, activated CD4(+) T cells promoted degranulation, and NKG2D- and NKp46-dependent IFN-gamma secretion by NK cells, probably owing to the capture of NKG2D and NKp46 ligands from the tumour-cell surface (trogocytosis). This effect was observed in CD4(+), CD8(+) and resting T cells, which showed substantial amounts of cell surface major histocompatibility complex class I chain-related protein A on co-culture with tumour cells. Our findings identify a new, so far, unrecognized mechanism by which effector T cells support NK cell function through the capture of specific tumour ligands with profound implications at the crossroad of innate and adaptive immunity.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19498463      PMCID: PMC2726665          DOI: 10.1038/embor.2009.92

Source DB:  PubMed          Journal:  EMBO Rep        ISSN: 1469-221X            Impact factor:   8.807


  14 in total

Review 1.  Surface NK receptors and their ligands on tumor cells.

Authors:  Lorenzo Moretta; Cristina Bottino; Daniela Pende; Roberta Castriconi; Maria Cristina Mingari; Alessandro Moretta
Journal:  Semin Immunol       Date:  2006-05-26       Impact factor: 11.130

2.  Capture of target cell membrane components via trogocytosis is triggered by a selected set of surface molecules on T or B cells.

Authors:  Denis Hudrisier; Anne Aucher; Anne-Laure Puaux; Christine Bordier; Etienne Joly
Journal:  J Immunol       Date:  2007-03-15       Impact factor: 5.422

3.  IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity.

Authors:  V Shankaran; H Ikeda; A T Bruce; J M White; P E Swanson; L J Old; R D Schreiber
Journal:  Nature       Date:  2001-04-26       Impact factor: 49.962

4.  Cutting Edge: IL-10-producing CD4+ T cells mediate tumor rejection.

Authors:  Benjamin M Segal; Deborah D Glass; Ethan M Shevach
Journal:  J Immunol       Date:  2002-01-01       Impact factor: 5.422

Review 5.  Intercellular transfer of antigen-presenting cell determinants onto T cells: molecular mechanisms and biological significance.

Authors:  Denis Hudrisier; Pierre Bongrand
Journal:  FASEB J       Date:  2002-04       Impact factor: 5.191

Review 6.  Immunosuppressive strategies that are mediated by tumor cells.

Authors:  Gabriel A Rabinovich; Dmitry Gabrilovich; Eduardo M Sotomayor
Journal:  Annu Rev Immunol       Date:  2007       Impact factor: 28.527

7.  CD4(+) T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-gamma.

Authors:  D Mumberg; P A Monach; S Wanderling; M Philip; A Y Toledano; R D Schreiber; H Schreiber
Journal:  Proc Natl Acad Sci U S A       Date:  1999-07-20       Impact factor: 11.205

8.  Trogocytosis-based generation of suppressive NK cells.

Authors:  Julien Caumartin; Benoit Favier; Marina Daouya; Christine Guillard; Philippe Moreau; Edgardo D Carosella; Joel LeMaoult
Journal:  EMBO J       Date:  2007-02-22       Impact factor: 11.598

9.  Intracellular retention of the NKG2D ligand MHC class I chain-related gene A in human melanomas confers immune privilege and prevents NK cell-mediated cytotoxicity.

Authors:  Mercedes B Fuertes; María V Girart; Luciana L Molinero; Carolina I Domaica; Lucas E Rossi; María M Barrio; José Mordoh; Gabriel A Rabinovich; Norberto W Zwirner
Journal:  J Immunol       Date:  2008-04-01       Impact factor: 5.422

10.  The intracellular granzyme B inhibitor, proteinase inhibitor 9, is up-regulated during accessory cell maturation and effector cell degranulation, and its overexpression enhances CTL potency.

Authors:  Claire E Hirst; Marguerite S Buzza; Catherina H Bird; Hilary S Warren; Paul U Cameron; Manling Zhang; Philip G Ashton-Rickardt; Phillip I Bird
Journal:  J Immunol       Date:  2003-01-15       Impact factor: 5.422

View more
  11 in total

1.  Different functional outcomes of intercellular membrane transfers to monocytes and T cells.

Authors:  Kiave-Yune HoWangYin; Estibaliz Alegre; Marina Daouya; Benoit Favier; Edgardo D Carosella; Joel LeMaoult
Journal:  Cell Mol Life Sci       Date:  2010-04       Impact factor: 9.261

2.  Trans-SILAC: sorting out the non-cell-autonomous proteome.

Authors:  Oded Rechavi; Matan Kalman; Yuan Fang; Helly Vernitsky; Jasmine Jacob-Hirsch; Leonard J Foster; Yoel Kloog; Itamar Goldstein
Journal:  Nat Methods       Date:  2010-10-10       Impact factor: 28.547

3.  Engineering lymph node homing of ex vivo-expanded human natural killer cells via trogocytosis of the chemokine receptor CCR7.

Authors:  Srinivas S Somanchi; Anitha Somanchi; Laurence J N Cooper; Dean A Lee
Journal:  Blood       Date:  2012-04-12       Impact factor: 22.113

4.  KIR-based inhibitory CARs overcome CAR-NK cell trogocytosis-mediated fratricide and tumor escape.

Authors:  Ye Li; Rafet Basar; Guohui Wang; Enli Liu; Judy S Moyes; Li Li; Lucila N Kerbauy; Nadima Uprety; Mohsen Fathi; Ali Rezvan; Pinaki P Banerjee; Luis Muniz-Feliciano; Tamara J Laskowski; Emily Ensley; May Daher; Mayra Shanley; Mayela Mendt; Sunil Acharya; Bin Liu; Alexander Biederstädt; Hind Rafei; Xingliang Guo; Luciana Melo Garcia; Paul Lin; Sonny Ang; David Marin; Ken Chen; Laura Bover; Richard E Champlin; Navin Varadarajan; Elizabeth J Shpall; Katayoun Rezvani
Journal:  Nat Med       Date:  2022-09-29       Impact factor: 87.241

Review 5.  Trogocytosis between Non-Immune Cells for Cell Clearance, and among Immune-Related Cells for Modulating Immune Responses and Autoimmunity.

Authors:  Ko-Jen Li; Cheng-Han Wu; Cheng-Hsun Lu; Chieh-Yu Shen; Yu-Min Kuo; Chang-Youh Tsai; Song-Chou Hsieh; Chia-Li Yu
Journal:  Int J Mol Sci       Date:  2021-02-24       Impact factor: 5.923

6.  Enhanced cytotoxicity of natural killer cells following the acquisition of chimeric antigen receptors through trogocytosis.

Authors:  Fu-Nan Cho; Tsung-Hsien Chang; Chih-Wen Shu; Ming-Chin Ko; Shuen-Kuei Liao; Kang-Hsi Wu; Ming-Sun Yu; Shyh-Jer Lin; Ying-Chung Hong; Chien-Hsun Chen; Chien-Hui Hung; Yu-Hsiang Chang
Journal:  PLoS One       Date:  2014-10-14       Impact factor: 3.240

7.  Anti-GPC3-CAR T Cells Suppress the Growth of Tumor Cells in Patient-Derived Xenografts of Hepatocellular Carcinoma.

Authors:  Zhiwu Jiang; Xiaofeng Jiang; Suimin Chen; Yunxin Lai; Xinru Wei; Baiheng Li; Simiao Lin; Suna Wang; Qiting Wu; Qiubin Liang; Qifa Liu; Muyun Peng; Fenglei Yu; Jianyu Weng; Xin Du; Duanqing Pei; Pentao Liu; Yao Yao; Ping Xue; Peng Li
Journal:  Front Immunol       Date:  2017-01-11       Impact factor: 7.561

8.  High-grade serous ovarian tumor cells modulate NK cell function to create an immune-tolerant microenvironment.

Authors:  Veronica D Gonzalez; Ying-Wen Huang; Antonio Delgado-Gonzalez; Shih-Yu Chen; Kenyi Donoso; Karen Sachs; Andrew J Gentles; Grace M Allard; Kevin S Kolahi; Brooke E Howitt; Ermelinda Porpiglia; Wendy J Fantl
Journal:  Cell Rep       Date:  2021-08-31       Impact factor: 9.423

Review 9.  Mechanisms of cellular communication through intercellular protein transfer.

Authors:  Khawaja Ashfaque Ahmed; Jim Xiang
Journal:  J Cell Mol Med       Date:  2010-01-11       Impact factor: 5.310

Review 10.  Secretory pathways generating immunosuppressive NKG2D ligands: New targets for therapeutic intervention.

Authors:  Aroa Baragaño Raneros; Beatriz Suarez-Álvarez; Carlos López-Larrea
Journal:  Oncoimmunology       Date:  2014-04-25       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.